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Purpose: We reviewed a 13-year experience with an emphasis on long-term survival and 
renal function response when renal artery reconstruction (RAR) was performed primarily 
for the preservation or restoration of renal function in patients who had atherosclerotic 
renovaseular disease. 
Methods: From January 1, 1980, to June 30, 1993, 139 patients underwent RAR for renal 
function salvage and were retrospectively reviewed. Inclusion criteria were either preop- 
erative serum creatinine level >2.0 mg/dl  (67% of patients) or RAR to the entire 
functioning renal mass irrespective of baseline renal function. Patient survival was 
calculated by life-table methods. Cox regression analysis was used to determine r lative risk 
(FUR) estimates for the late outcomes of continued eterioration ofrenal function and late 
s~vival after RAIL A logistic regression model was used to evaluate variables as ociated 
with perioperative complications. 
Results: Clinical characteristics of the cohort were notable for advanced cardiac (history of 
congestive heart failure, 27%; angina, 22%; previous myocardial infarction, 19%) and renal 
diisease (serum creatinine level <2.0 mg/dl,  33%; 2.0 mg/di  to 3.0 mg/dl,  40%, >3.0 
mg/dl,  27%). Cardiac disease was the principle cause of early (6 of 11 operative deaths) and 
late death. Operative management consisted of aortorenal bypass in 47%, extraanatomic 
bypass in 45%, and endarterectomy in 8%; 45% of patients required combined aortic and 
RAIL The operative mortality rate was 8%; significant perioperative r nal dysfunction 
occurred in 10%. Major operative morbidity was associated with increasing azotemia 
(I~R = 2.1; p = 0.001; 95% confidence interval [CI], 1.3 to 4.7 for each 1.0 mg/d l  
increase in baseline creatinine l vel). Of those patients who had a baseline creatinine l vel 
>12.0 mg/dl,  54% had >20% reduction in creatinine level after RAIL Late follow-up data 
were available for 87% of operative survivors at amean duration of 4 years (range, 6 weeks 
to 12.6 years). Actuarial survival at 5 years was 52% + 5%. Continued eterioration i  renal 
fimction occurred in 24% of patients who survived operation, and eventual dialysis was 
required in 15%. Deterioration of renal function after RAR was associated with increasing 
levels of preoperative creatinine (RR = 1.6; 95% CI, 1.2 to 1.8; p = 0.001 for each 1.0 
mg/d l  increment in baseline creatinine l vel), and inversely related to early postoperative 
improvement in ereatinine l vel (RR = 0.41; 95% CI, 0.2 to 0.9; p = 0.04). 
Conclusions: Intervention before major deterioration i renal function and an aggressive 
posture toward the frequently associated coronary artery disease are necessary to improve 
long-term results when RAR is performed for renal function salvage. (J Vase Surg 
1996;24:371-82.) 
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Impairment of glomerular excretory function in 
association with hemodynamically significant renal 
artery stenosis has been referred to as "ischemic 
nephropathy," a term that describes a clinical circum- 
stance rather than a specific pathologic entity3 Al- 
though it has been recognized for more than 30 years 
that renal artery reconstruction (RAR) can potentially 
reverse renal dysfunction, 2 even to the dramatic 
extent of discontinuing dialysis therapy, s optimal 
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patient selection for renovascular reconstruction to
salvage or reverse renal dysfunction remains ill-de- 
fined. A recent clinical review that considered more 
than 500 patients who were treated with surgery or 
angioplasty during the past decade indicated that 
although these interventions improved renal function 
in some 50% of patients another 25% had a deterio- 
ration in renal function or died as a complication of 
their treatment. 4 It is generally acknowledged that 
diffuse atherosclerosis, and coronary artery disease in 
particular, is prevalent s and constitutes the principle 
limitations on longevity in patients who are treated for 
atherosclerotic renovascular disease (RVD) .  6-9 FUr- 
thermore, the immediate renal function response to 
revascularization is often limited or, in fact, prevented 
by the almost universally present renal parenchymal 
disease. 1° Renal parenchymal disease may be unre- 
lated to the large-vessel RVD per se, as in the 
circumstance of nephrosclerosis from longstanding 
hypertension, diabetic nephropathy, or in the case of 
renal atheroembolism, the renal and juxtarenal aortic 
athcrosclerosis may be directly responsible for renal 
parenchymal damage. 11 
Assessment ofthe functional result ofrenovascular 
reconstruction may be problematic. With the notable 
exception of the carefully and prospectively studied 
patients of Dean's groups, ~,3,8,1° the outcome param- 
eters of renal function response generally are limited 
to the sequential determination of serum crcatininc 
levels; the clinically important endpoints of death and 
the institution of dialysis are perhaps the best param- 
eters of the clinical value of RAR when performed for 
the salvage of renal function. 12 This statement, of 
course, implies that adequate follow-up data are 
available to formulate meaningful conclusions. In this 
report, we emphasize late functional outcome and 
survival data in a consecutive 13-year experience 
wherein RAR procedures for atherosclerotic disease 
were performed for the preservation orrestoration of 
renal function. 
PATIENTS AND METHODS 
From January 1, 1980, to June 30, 1993 (chosen 
to ensure aminimum 2-year follow-up), 139 consecu- 
tive patients who had atherosclerotic disease under- 
went RAR for the preservation orrestoration of renal 
function. This group represented 44% of the patients 
who underwent RAR for atherosclerotic disease dur- 
ing this period. The inclusion critcrium was an RAR 
procedure performed primarily for renal function 
salvage, defined either by a baseline serum creatinine 
level >2.0 mg/dl  (67% of patients) or by a serum 
creatinine <2.0 mg/dl  in a patient in whom RARwas 
performed to the entire functioning renal mass (bi- 
lateral RAR/unilateral PAR with contralateral ne- 
phrectomy, unilateral RAR to a single functioning 
kidney; see below). Thirty-two percent of the cohort 
met both parts of the inclusion criterium. Patients in 
whom an RAR procedure was performed for fibro- 
muscular disease, trauma, and rcimplantation fnon- 
stenotic renal arteries during the course of aortic 
surgery were excluded. Clinical, demographic, and 
follow-up data were obtained by a review of original 
hospital and physician's or surgeon's records. Current 
follow-up data were obtained at a return visit either to 
our clinic or with local physicians. Follow-up infor- 
mation was available for 85% of patients. 
Definitions. For the purposes of recording pre- 
operative clinical information, perioperative results 
and complications, late renal function response, and 
survival, the following definitions were used. A his- 
tory of congestive heart failure was defined as current 
or previous hospitalization for that condition. Hyper- 
tension was considered "poorly controlled" if the 
diastolic blood pressure was _> 100 mm Hg on multiple 
determinations in the hospital before surgery, and 
recent acceleration of hypertension was noted if the 
number of medications doubled or if the diastolic 
blood pressure became "poorly controlled" in the 6 
months before surgery. The response of the hyper- 
tensive condition to the RAR procedure was defined 
by previously published criteria 1a (cured patients were 
normotensive [diastolic blood pressure <90 mm Hg] 
without medications; improved patients were normo- 
tensivc with therapy, had a diastolic blood pressure 
_>15% below baseline, or had elimination of two or 
more antihypertensive medications). The baseline 
serum creatinine l vel was the level that was recorded 
closest o the date the patient underwent surgery. 
Recent deterioration i renal function was recorded 
when the serum creatinine l vel had doubled in the 12 
months before surgery. Patients were considered to 
have a "single functioning kidney" if any of the 
following criteria (regarding the contralateral kidney) 
were met: (1) surgically or congenitally absent kidney; 
(2) no visible ncphrogram on contrast arteriogram; or
(3) < 10% of total renal function in a kidney, as assessed 
by Technicium 99 renal scintigraphy. 
A history of cercbrovascular disease was consid- 
ered as any previous troke, transient ischemic attack, 
or carotid cndarterectomy. Leg occlusive disease was 
considered present in patients who had either claudi- 
cation, rest pain, or gangrene, or had undergone a 
previous leg bypass procedure or amputation. M1 
patients underwent contrast arteriography. Death 
within 30 days of surgery was considered operative 
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death; major cardiac omplications were any myocar- 
dial infarctions documented by sequential cardiac 
enzymes, any cardiac event hat resulted in transfer to 
an intensive care unit, or any cardiac event hat was 
considered to have prolonged hospitalization. Major 
pulmonary complications included the requirement 
for >48 hrs of postoperative ntilation, pneumonia 
verified by a chest roentgenogram, and any respira- 
tory event hat resulted in transfer to an intensive care 
unit. Renal-related complications were considered 
major if dialysis was required after surgery unless uch 
therapy had been present before operation, or if a 
patient's preoperative creatinine level had doubled. 
For the purposes of assessing the early and late renal 
function response to revascularization, the following 
definitions were used: improvement in renal function 
required a >-20% reduction in the creatinine level; 
renal function was considered as having worsened ifa 
>20% increase in the creatinine level occurred. Pa- 
tients who had lesser degrees of change in creatinine 
level after RAR was performed were considered to 
have "stable" renal function. Late outcomes with 
respect o renal function response were classified as 
"continued eterioration" for patients who went on 
to dialysis, died of renal-related causes during follow- 
up, or had late creatinine l vels two times the baseline 
value or :more. 
Statistical methods. All statistical computations 
were performed on a DEC VAX 11780 computer 
(Digital Equipment Corp., Maynard, Mass.) with the 
use of the following statistical modules: BMDP4F 
(frequency tables), BMDP1L (survival analysis), 
BMDP2L (Cox proportional hazards regression) and 
BMDPLR (logistic regression). Frequency tables 
were analyzed for statistical significance with Z 2 or 
Fisher exact ests, and the Mantel-Cox test was used to 
compare survival curves. Life tables were constructed 
for the determination of late survival rates. A Cox 
proportional hazards regression model was developed 
to derive relative risk (RR) estimates for late out- 
comes. A logistic regression model was created to 
evaluate variables associated with perioperative com- 
plications. 
RESULTS 
Preoperative clinical profile. Clinical and demo- 
graphic features of the study group are displayed in 
Table I. They are representative of a patient cohort 
with diffuse atherosclerosis. Hypertension was uni- 
versal, and more than 50% of patients were taking 
more than three antihypertensive medications. As 
displayed in Table I, significant (creatinine l vel >_2.0 
mg/dl)  baseline renal insufficiency was present in two 
Table I. Demographic and clinical features 
Variable n (%) 
Age (mean, range) 67 yr (40 to 90) 
age >70 yr 54 (39) 
Male 74 (53) 
History of smoking 70 (50) 
Diabetes 21 (15) 
Hypertension 137 (99) 
Poorly controlled 48 (34) 
Recent acceleration 50 (36) 
Renal insufficiency ( creatinine 109 ( 78 ) 
_>h5 mg/dl) 
Serum creatinine l vel <2.0 47 (33) 
mg/dl 
Serum creatinine l vel 2.0- 55 (40) 
3.0 mg/dl 
Serum creatinine l vel >3.0 37 (27) 
mg/dl 
Single functioning kidney 63 (45) 
thirds of patients, and only 22% had a preoperative 
serum creatinine level in the normal range (_<1.5 
mg/dl).  Recent deterioration i renal function was 
noted in 25%, but only three patients were undergo- 
ing dialysis therapy before the RAR procedure. Ex- 
trarenal atherosclerotic disease was commonplace, as
displayed in Table II. Clinically manifest coronary 
artery disease (previous myocardial infarction, history 
of angina, history of congestive heart failure, or 
previous coronary artery bypass grafting procedure) 
was common, yet few patients underwent specific 
preoperative cardiac testing with dipyridamole thal- 
lium scintigraphy (19%) or coronary angiography 
(7%). Five patients underwent a coronary artery 
bypass grafting procedure in the 3 months before 
RAR. Surgery was restricted to patients who had 
high-grade (>-75% diameter stenosis) lesions or occlu- 
sions, and 13% of treated arteries were totally oc- 
cluded before RAIL was performed. 
Surgical management and perioperative re- 
suits. As displayed in Fig, 1, a spectrum of surgical 
techniques was used. Combined aortic and renal 
artery grafting procedures were performed in 45% of 
patients, with equivalent (45%) use of extraanatomic 
bypass procedures. Unilateral RAR procedures were 
performed in87% of patients and bilateral reconstruc- 
tion in 13% (eight of I8 with staged bilateral repair). 
Contralateral nephrectomy was performed in 11%. 
Recognized perioperative graft thrombosis was iden- 
tified in five patients (4%), three of whom underwent 
immediate and successful revision. The operative 
mortality rate was 8% (11 of 139); the causes of 
perioperative deaths and significant complications are 
detailed in Table III. Cardiac-related events ac- 
counted for the majority of the complications and 
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Fig. 1. Operative management of RVD. A total of 147 procedures were performed in 139 
patients. Eight patients underwent s aged bilateral RAR procedures. 
deaths. In considering the 21 patients who either died 
in the perioperative period or had major cardiopul- 
monary complications, only increasing azotemia 
(RR = 2.1; p = 0.001; 95% confidence interval [CI], 
1.3 to 4.7 for each 1.0 mg/dl  increase in preoperative 
creatinine) was associated with such complications 
and deaths.. 
Other variables that were assessed but that were 
found not to be associated with major perioperative 
complications included age, diabetes, clinical evi- 
dence of coronary artery disease, history of cere- 
brovascular or peripheral vascular disease, and com- 
bined aortic reconstruction and RAR. Dialysis was 
instituted after surgery in six patients (4%; excluding 
three patients on dialysis before surgery), and half of 
them needed permanent dialysis. All but one of these 
patients had a preoperative creatinine level >3.0 
mg/dl.  Dialysis was being used before surgery in only 
three patients, and RAR was successful in eliminating 
this need in one patient; the other two died in the 
perioperative period. The immediate impact of RAR 
on renal function was assessed with serum creatinine 
determinations at hospital discharge or 1 month after 
surgery. By the stringent criteria of a _>20% reduction 
in the creatinine l vel at the time of hospital discharge, 
54% of patients who had an initial creatinine l vel _>2.0 
mg/dl  demonstrated improvement in renal function. 
Seventy-three p rcent of patients had either stable or 
improved renal function within 1 month of RAR, and 
of a variety of clinical variables examined only revas- 
cularization to a single functioning kidney (p -_- 0.04) 
and a significant diminution in postoperative antihy- 
pertensive medication requirement (p = 0.04) were 
associated with immediate improvement orstability in 
renal function. 
Late functional outcomes and survival. Fol- 
low-up data, at a mean duration of 48 months (range, 
6 weeks to 12.6 years), were available for 87% of the 
patients who survived operation. The response to 
RAR in terms of hypertension control was favorable. 
Although cure of hypertension was rare (8% of pa- 
tients), an additional 71% of patients demonstrated 
improvement in hypertension control at the time of 
the last follow-up. Long-term improvement orstabil- 
ity in renal function was noted in 76% of late surviving 
patients (n= 51) at a mean duration of 4.8 years 
(range, 4 months to 12.5 years). Dialysis was insti- 
tuted during the follow-up period in 17 patients (15% 
operative survivors) at a mean interval of 38 months 
after operation (range, 2 to 96 months). Patients who 
eventually required ialysis, those who died of renal 
failure without institution of dialysis, and those whose 
serum creatinine l vels at least doubled over baseline 
values could be broadly considered as the group with 
continued eterioration i  renal function. Late occlu- 
sion of the RAR could be identified as having con- 
tributed to this deterioration i only four patients. 
Late renal function deterioration occurred in 24% of 
107 patients for whom adequate follow-up informa- 
tion was available. Cox analysis revealed a strong 
association of late functional deterioration with in- 
creasing preoperative serum creatinine levels. The 
relative risk for the continued eterioration of renal 
function was 1.6 (p = 0.001; 95% CI, 1.2 to 1.8) for 
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Table II. Associated vascular diseases Table III. Perioperative complications 
Disease site n (%) Factor n (%) 
Documented coronary artery disease 76 (55) 
History of congestive heart failure 37 (27) 
History of angina 31 (22) 
History of myocardial infarct 27 (19) 
Prior CABG* 13 (9) 
Cerebrowtscular 43 (31) 
Lower extremity occlusive 70 (50) 
Aortic aneurysm 68 (49) 
CABG, coronary artery bypass grafting procedure. 
See text for inclusion criteria. 
*Excludes five patients who underwent CABG <3 months before 
surgery. 
each 1.0 mg/dl increment in basement creatinine 
level. As displayed in Fig. 2, A and B, the probability 
of continued deterioration in renal function after 
RAR was significantly increased when patients were 
divided according to different threshold levels of 
preoperalcive azotemia. The probability of continued 
deterioration in renal function was striking 
(p= 0.0007) for those patients who had baseline 
creatinine levels >_3.0 mg/dl. Other variables that 
were inversely associated with continued renal func- 
tion deterioration were the notation of early postop- 
erative improvement in renal function (RR= 0.41; 
95% CI, 0.2 to 0.9; p= 0.04) and a significant 
reduction in the number of early postoperative anti- 
hypertension medications required (RR = 0.03; 95% 
CI, 0.0 to 0.5; p = 0.02). 
Cumulative survival data for the study group 
(operative deaths included) are displayed in Table IV. 
The median length of survival after operation was 5.6 
years, but the survival rate at 5 years was only 
52% __ 5%. Univariate predictors of late death in- 
cluded diabetes (p < 0.06), treatment for associated 
abdominal aortic aneurysm (p < 0.02), and a history 
of preoperative congestive heart failure (p < 0.03). 
The survival rate among patients who eventually 
required ialysis after operation was poor, with 11 of 
17 such patients dying (65%), seven within 1 year of 
the institution of dialysis. The impact of baseline renal 
insufficiency on late death was significant. The relative 
risk of late death was 1.5 (p = 0.001; 95% CI, 1.3 to 
1.7) for each 1 mg/dl increment in preoperative 
creatinine level, and late survival could be differenti- 
ated significantly (p = 0.008) by a threshold of pre- 
operative creatinine l vel greater than or less than 2.0 
mg/dl (Fig. 3). An even greater negative impact on 
late survival was noted for those patients who had a 
history of congestive heart failure (RR=I.9;  
p = 0.01; 95% CI, 1.1 to 3.1). Causes of late death are 
displayed in Table V. 
Death within 30 days of surgery 11 (8) 
Myocardial infarction 6 
Perioperative hemorrhage 2 
Stroke 2 
Ruptured AAA 1 
Nonfatal cardiac omplications * 21 (15) 
Major 13 
Minor 8 
Pulmonary complications * 2 0 (15) 
Major 13 
Minor 7 
Major renal complications* 14 (10) 
Early thrombosis reconstruction 5 (4) 
AAA, abdominal ortic aneurysm. 
*See text for definition. 
DISCUSSION 
Available natural history data have demonstrated 
that atherosclerotic RVD is progressive and is often 
accompanied by a deterioration i overall renal func- 
tion. 14q9 Despite the lack of controlled trials, a 
general consensus exists that performing RAR for 
renal function salvage can provide favorable results, 
occasionally to the extent of reversing the need for 
dialysis in selected patients? '4It also has been empha- 
sized that the patients' profile is one of advanced age 
and systemic atherosclerosis and that the indications 
for intervention have shifted from control of hyper- 
tension alone to RAR for renal function salvage. 6-9,2° 
The clinical characteristics in our patients (Tables I
and II) are consistent with multiple other contempo- 
rary reports and continue to emphasize that long- 
term results in these patients are often limited by 
extrarenal atherosclerosis--in particular, associated 
coronary artery disease. Our series emphasizes the 
importance of cardiac disease, both with respect o 
surgical complications and with respect to limitations 
on longevity (Table V). We and others have empha- 
sized that the detection and treatment of associated 
coronary disease iscommonplace and is an important 
factor in the current safety of RAR .8,21 In contempo- 
rary practice, approximately 60% of our patients have 
undergone specific cardiac evaluations, and fully 40% 
of patients who are treated with combined aortic 
reconstruction and RAR have undergone surgery 
with antecedent mechanical correction of their coro- 
nary artery diseaseY The corresponding figures in 
this report (preoperative dipridamole thallium study, 
19%; previous CABG, 9%) reflect earlier practice 
patterns. 
Inclusion criteria as to which patients, which 
variations of RVD anatomy, and which procedures 
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Fig. 2. Life-table analysis of likelihood of continued eterioration in renal function after RAR, 
stratified by preoperative baseline serum creatinine levels less than or greater than 3.0 mg/dl (A) 
and less than or greater than 2.0 mg/dl (B). 
constitute renovascular surgery for function salvage 
vary widely. On the basis of the original reports of  
Dean et al., 1° which suggested that revascularization 
to the entire functioning or potentially functioning 
renal mass was an important variable correlated with 
successful RAR, we included in this review those 
patients whose RAR encompassed all potentially func- 
tioning renal mass, irrespective of preoperative global 
renal insufficiency. Similar criteria for patient inclu- 
sion in the spectrum of RAR for function salvage have 
been reported by Libertino et al.22 and Novick et al.2° 
Others have chosen some arbitrary level of renal 
insufficiency (typically a serum creatine level _>1.8 to 
2.0 mg/dl)  as the inclusion criteria. 7,12 Perhaps more 
important is the percentage of  patients who have 
extreme (serum creatinine l vel > 3.0 mg/dl)  baseline 
renal insufficiency. 
One-third of the patients reported in our study 
had such extreme renal insufficiency before operation, 
a proportion that is consistent with other contempo- 
rary reports. 6-8a2,22 It can be anticipated that the 
reported results for tLAR, particularly late outcome 
parameters, will vary in accordance with the clinical 
characteristics in a particular series. Hansen et al. 8 
noted the poor outcome (nearly 50% mortality rate) at 
4 years in patients who had "extreme" disease (creat- 
inine level _>3.0 mg/d l  with diffuse atherosclerotic 
cardiovascular disease or evidence of left ventricular 
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Fig. 3. Life-table survival curves for patients treated who had baseline serum creatinine l vels 
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dysfunction). Our data detailing the negative impact 
of increasing azotemia nd previous congestive heart 
failure on late survival are quite similar. Furthermore, 
late survival in our series is significantly worse than we 
previously reported when all patients who underwent 
RAR for RVD at our institution are considered (Fig. 
4). In comparing these groups of patients, the severity 
of the PCVD and renal dysfunction is the principle 
difference. Because cardiac disease is the principle 
source of late death, this suggests a quantitative 
relationship between the RVD and cardiac disease, as 
noted by others: 
Criteria for assessing renal function response and 
what constitutes improved, stable, or worsened renal 
function have varied. Some authors have designated a 
>20% change from baseline serum creatinine level as 
constituting a significant change in either direction2°; 
Hallett et al. 6 consider an absolute 1.0 mg/d l  of 
serum creatinine change as significant; others have 
used lesser changes from baseline creatinine values to 
define the response to RAR.  22-24 In our report, we 
have emphasized late outcome endpoints and ac- 
knowledge the imprecision of serum creatinine l vels 
in assessing the early response to RAR, as emphasized 
by others. 12 Dean et al. 1° demonstrated that in pa- 
tients who had modest preoperative azotemia (creat- 
inine level <2.0 mg/dl) ,  early improvements in serum 
creatinine l vel were not evident despite the fact that 
most of these patients had measurable improvement 
in glomerular filtration rate) ° The term "stable" 
renal function, which is more properly stated "un- 
changed" in considering short-term outcomes, only 
has meaning with adequate follow-up duration. The 
clinically relevant endpoints of patient survival and 
eventual dependence on dialysis therapy can only be 
assessed from reports that contain adequate follow-up 
data. Our series, with a mean follow-up duration of 4 
years, compares favorably with the bulk of the avail- 
able literature in this regard. The series that are 
summarized by Rimmer and Grennari 4 and reports 
that appeared subsequent tothat review either eport 
short-term results or follow-up intervals that average 
approximately 2 ears. 6'24 It seems logical to conclude 
that the rates of survival and progression to dialysis 
will vary in accordance with follow-up duration. 
Alternatively, the eventual need for dialysis in our 
patients (1 5% of late survivors) does not differ signifi- 
cantly from the 7%-to- 18% range that was reported in 
four recent reports from centers with acknowledged 
expertise whose mean follow-up interval ranged from 
less than 2 years to 4 years. 6'8:2'23 The majority of our 
patients began dialysis within 2 years of RAR, which is 
consistent with the hypothesis of Dean et al.1 that 
ischemic nephropathy is a rapidly progressive disease. 
The implication isthat many patients are treated with 
RAR when their vascular and renal parenchymal 
disease is at a relatively advanced stage, and RAR 
represented a desperate and often failed attempt to 
alter the clinical course of the disease. 
The significant impact of what others have termed 
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Table IV. Long-term survival data for 139 patients after renal artery reconstruction 
Patients Patients Proportion 
Interval (yr) No. of patients withdrawn dead dead 
Cumulative 
proportion 
surviving at 
Proportion beginning of 
surviving interval 
0-1 139 20 29 0.2533 0.7752 1.0000 
1-2 90 3 8 0.0904 0.9096 0.7752 
2-3 79 9 9 0.1208 0.8792 0.7051 
3-4 61 9 4 0.0708 0.9292 0.6194 
4-5 48 6 4 0.0889 0.9111 0.5760 
5-6 38 4 3 0.0833 0.9167 0.5248 
6-7 31 7 1 0.0364 0.9636 0.4811 
7-8 23 7 5 0.2564 0.7436 0.4636 
8-9 11 2 3 0.3000 0.7000 0.3447 
Table V. Causes of late death 
Factor No. of late deaths (%) 
Cardiac 21 (37) 
Renal 6 (11) 
Malignant disease 9 ( 16 ) 
Stroke 6 (11) 
Miscellaneous 10 (18) 
Gastrointestinal-perforated viscus 3 
Multisystem organ failure 4 
Ruptured AAA 1 
Mesenteric ischemia 2 
Unknown 4 (7) 
Total 56 
AAA, abdominal ortic aneurysm. 
"extreme" baseline renal insufficiency (serum creati- 
nine level >3.0 mg/dl)  in predicting the continued 
deterioration of renal function in our patients is a 
finding that is noted in most reports that detail ate 
outcomes. Hallett et al.6 reported that 35% of patients 
who had a baseline creatinine level >3.0 mg/d l  who 
were treated with RAR began undergoing dialysis less 
than 2 years after operation. Chaikoff et al. 12 noted 
nearly identical findings, with an estimated probabil- 
ity of requiring dialysis of at least 30% at 2 years for 
patients who had poor preoperative functional reserve 
(creatinine l vel >3.0 mg/dl).  In the recent report of 
Hansen et al., 8 dialysis was eventually required in 7% 
of 157 patients who underwent RAR for atheroscle- 
rotic disease, but only half of these patients had initial 
creatinine levels >2.0 mg/dl .  Virtually all patients 
who underwent dialysis had extreme (creatinine l vel 
_>3.0 mg/dl)  baseline renal insufficiency or were 
already dialysis-dependent before operation. Novick 
et al. 2s suggested that performing RAR procedures i  
not worthwhile when serum creatinine l vels exceed 
4.0 mg/di  because irreversible renal parenchymal 
damage already will have occurred. Yet a subgroup of 
patients (25% in our series) who had even extreme 
preoperative renal insufficiency will benefit from 
RAR. The report ofHansen et al.,3 which focused on 
dialysis-dependent pa ients, is notable in that dialysis 
had been instituted a mean of 3 weeks before surgery, 
and rapid preoperative decline in renal function char- 
acterized this group. Many of their patients had acute 
clinical deterioration similar to those reported by 
Messina et alY who had recurrent pulmonary edema. 
This suggests that the clinical context of patients' 
presentation when extreme l vels of renal dysfunction 
are present may be an important variable in predicting 
the response to RAR. 
The surgical approach when RARis performed for 
function salvage has evolved, both related to comor- 
bidity considerations and with accumulating evidence 
that a comprehensive bilateral reconstruction affords 
the best opportunity for function restoration? ,6,1° 
Bilateral RAR or RAR with contralateral nephrec- 
tomy was performed in only 23% of our patients, and 
the high percentage of patients (45%) who had a 
single functioning kidney partially accounts for this 
number. It is possible, even likely, that some of our 
patients could have benefitted from bilateral, more 
comprehensive r vascularization. This possibility, of 
course, relates to the lower limits of function restora- 
tion by RAR performed in small, compromised kid- 
neys, most of which harbor total chronic occlusions. 
We believe that distal arterial reconstitution on the 
late phase of arteriography remains the best single 
predictor of the value of RAR in this setting. 1° 
However, limiting characteristics imposed by fixed 
renal disease and clinical factors such as diabetes 
remain undefined and are worthy of further study. 
Our preference for performing extraanatomic bypass 
procedures when unilateral RARis indicated, and the 
favorable results with this approach, have been previ- 
ously described. 9 The percentage of patients who 
were treated with combined aortic reconstruction 
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Fig. 4. Comparative life-table survival curves for the present series and a consecutive s ries 9 of 
all patients who underwent RAR for atherosclerotic disease at our institution. There is a 
significant (p< 0.0012) decrease in late survival in the present series, i.e. the subgroup 
undergoing RAR for renal function salvage. 
and RAR (45% in this series) is typical of contempo- 
rary repo,rts that consider RAR for atherosclerotic 
disease. 3'6'23 In our practice, the combined operation 
now accounts for 50% of all RAR procedures, and 
there has been a corresponding 10% decrease in the 
use of extraanatomic bypass procedures during the 
past 5 years. Although performed infrequently in our 
series, transaortic endarterectomy is commonly ap- 
plied in current practice in circumstances of bilateral 
simultaneous RARor combined aortic reconstruction 
and RAR. 6'21 The operative mortality rate in our series 
is consistent with that of other studies that encompass 
the same time interval, z 27,28 Operative complications 
generally have been concentrated in those patients 
who had multiple comorbid conditions and their 
association with severe levels of azotemia demon- 
strated in this report and others.6,8 The morbidity rate 
of RARis cited in the rationale for treating RVD with 
catheter-based interventions. The surgery and angio- 
plasty series summarized by Rimmer and Grennari, 4 
however, demonstrated quivalent procedure-related 
mortality rates for surgery and angioplasty. Further- 
more, even recent reports relative to the use of 
angioplasty or stents for RVD continue to detail 
inferior anatomic and clinical results 2931 when com- 
pared with the durability of surgical RAIL 9 Largely 
related to the anatomic fact that most RVD is an 
extension of aortic atherosclerosis, we believe that 
surgical ILA_Ris the preferred approach for the major- 
ity of these patients. 
On the basis of this experience, we conclude that 
intervention before major deterioration i  renal func- 
tion and an aggressive posture toward the detection 
and treatment of the frequently associated coronary 
artery disease will be necessary to improve late results 
when RAR is performed for renal function salvage. 
Although the survival data reported herein are sober- 
ing, they do compare favorably with the expected 
clinical course of patients with atherosclerofic disease 
who come to dialysis. 32 Detection of patients who 
have RVD at an earlier stage of clinical deterioration 
by screening of high-risk patient groups holds prom- 
ise. 33,84 Further prospective study of the clinical and 
renal pathologic variables that might predict the 
response to RAIl, is warranted. 
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D ISCUSSION 
Dr. Steven J. Burnham (Chapel Hill, N.C.). I con- 
gratulate the authors on this commendable presentation. 
The material complements your publication in the June 
issue of  the Journal of Vascular Surgery that dealt with 
simultaneous aortic reconstruction and RAIL 21 
This report covers 139 patients during a 13-year period. 
It represents 44% of the RAR procedures that were per- 
formed during that period of  time. I would ask about the 
larger cohort of  RARprocedures performed in patients who 
did not meet your inclusion criteria. Were the reconstruc- 
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tions performed for hypertension i  patients who had 
normal creatinine l vels? 
In the one third of the patients who had preoperative 
serum creatinine l vels <2 mg/dl ,  I would assume that the 
reason for referral to a vascular surgeon was not progressive 
deterioration i renal function. Were these patients een 
because of leg occlusive disease and found to have renal 
artery stenosis at the time of aortography? If so, could you 
please share with us your indications for performing RAILs 
in lesions found incidentally on aortograms? 
The 45% of patients who had extraanatomic reconstruc- 
tions might deserve further comment. Was there a differ- 
ence in preoperative s rum creatinine l vels compared with 
patients who underwent aortorcnal bypass or cndarter- 
ectomy? 
Finally, the endpoints of this review were changes in 
serum creatinine l vel, death, and the institution of dialysis. 
I think the life-table data are similar to those for major leg 
vascular reconstructive procedures and probably reflect he 
continuation of the primary disease process rather than the 
technical excellence of the reconstructive procedure. I 
suspect that there are no differences in the life tables if you 
compare the aortorenal reconstructions with the visceral 
artery with renal reconstructions. I  this true? 
You certainly have data for the life-table analysis to 
describe the preservation of renal function with the criteria 
that you define. I think this is very interesting and can teach 
us about he impact of operation on prevention of the need 
for dialysis. I think it is interesting to look at this and 
compare the two major types of renal reconstructions, and 
this might guide our aggressiveness in approaching these 
patients. I also think that this will be benchmark for our 
colleagues in interventional radiology. 
Dr. Richard P. Cambria. You asked about the larger 
cohort of patients who underwent a surgical RAR proce- 
dure for atherosclerotic disease during the same time 
interval; I did show that data, although they are not 
contained in the manuscript. The principle difference in the 
clinical factors was referable to the morbid sequelae of RVD, 
that is, the incidence of patients who had renal insufficiency 
and a single functioning lddney. Other clinical and demo- 
graphic data, including age, incidence of coronary disease, 
and so forth, were no different between the two cohorts. 
With respect to the mode of referral of these patients, 
that data was not specifically included in the manuscript. 
Approximately 80% of these patients were referred either 
with the knowledge or the suspicion of RVD or combined 
aortic and renovascular disease. As the vascular surgeons in 
the audience are likely aware, it is not uncommon to have a 
patient referred for "aneurysm resection" only to find out 
that the patient has a serum creatinine l vel of 2 mg/dl ,  one 
shriveled kidney, and a stenosis in the artery to the remain- 
ing kidney. We certainly believe that these patients fit into 
the general category in which RAR is performed for the 
salvage of function, despite the fact that their initial mode of 
referral may not have included this procedure. We found in 
a review of all of these patients that roughly half of them will 
come with antecedent lmowledge or the suspicion of RVD 
and half of them will be referred for manifestations of their 
aortic disease, and it is not uncommon then for the vascular 
surgeon to discover both anatomic and fimctionally severe 
RVD. 
With respect to our criteria for intervention after finding 
RVD during aortography for associated aortic disease, this 
runs the spectrum. Many of these patients will have func- 
tionally significant RVD. The controversial point, of course, 
relates to those who do not, who have undergone so-called 
"prophylactic" RAP,, as will be discussed in a later presen- 
tation. In our report in the June 1995 issue of Journal of 
Vascular Surgery, we have advocated an aggressive posture 
towards the so-called "incidentally" discovered renal artery 
stenosis on the basis of the available natural history of that 
disease process.211 certainly admit hat that is a controversial 
stance, and of our combined aortic and renal graft opera- 
tions only 5% of the RARs were considered "prophylactic." 
With respect to the extraanatomic versus the combined 
aortic and renovascular operations, there was no difference 
in the clinical or demographic features between these two 
groups, and we have used the extraanatomic bypass grafting 
procedures for unilateral reconstruction for more than 20 
years at our institution, and we believe they are worthwhile 
procedures. I will add, however, with respect to the mode 
and technique of revascularization, that endarterectomy is 
now our preferred technique for the patient who requires 
bilateral simultaneous operation. Only 20% of the patients 
in our series underwent bilateral reconstruction, and our 
report in the June 1995 issue of Journal of Vascular Surgery 
verifies that in contemporary practice that percentage has 
greatly increased. 2I 
With respect to the life-table survival rate, we showed 
that for all patients in our unit who have undergone RAR 
procedures the 5-year actuarial survival rate is distinctly 
better than that reported for our present cohort, and we 
think that survival rate this reflects both more severe renal 
insufficiency and a quantitative relationship between the 
severity of the RVD and the coronary disease, as has been 
reported by Dr. Valentine of this Society. 
Dr. Ronald J. Stoney (San Francisco, Calif.). I would 
like to ask you about the 25% of your patients whose renal 
function continued to decline after the operation. This 
event was unanticipated and certainly was not the objective 
of the operation. These patients could have had progressive 
impairment of renal flow through their reconstruction. I am 
wondering what surveillance methods you used, what you 
did when you detected this problem, if you did, and what 
your current methods are for surveillance, be it arteriogra- 
phy, magnetic resonance angiography, or duplex. 
Dr. Cambria. This was a retrospective r view, and 
certainly no routine method of late surveillance of the 
reconstruction was used. We do have data for the patients 
who went on to have continued renal function deteriora- 
tion, because they were looked at closely. In only four of 
those patients could we discover a technical or anatomic 
problem with the RARprocedure as a possible contributing 
factor to their late deterioration i  renal function. Our data 
with respect to the durability of all the different modes of 
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RARhas been published previously, and we believe it is fair 
to say that the majority of technical failures occur early on. 
Currently, I like to observe these patients with renal scans 
and clinical variables. For many of the patients who have 
undergone reconstruction toa single functioning kidney, it 
is quite obvious on the basis of clinical and laboratory 
grounds whether or not the reconstruction is at least patent, 
although up until recently with the magnetic resonance 
angiography there has been no good noninvasive way to 
observe these patients. 
Dr. Jose Alvarez, Jr. (Miami, Fla.). How many of these 
patients underwent failed percutaneous treatment of the 
renal artery disease, how many patients had stents placed, 
and how do you deal with the 80-year-old patient who has 
diffuse atherosclerotic disease, renovascular hypertension, 
and coronary disease--which is the usual type of patient we 
see here in Florida? 
Dr. Cambria. None of the patients had stents placed 
because the inclusive period was only up to 1993, and there 
were only a few patients in the series who underwent a failed 
previous angioplasty procedure. At our institution, surgical 
reconstruction remains the preferred method for interven- 
tion for RVD, although we certainly haven't gone about in 
any prospective fashion to look at the results of performing 
angioplasty procedures. 
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